Abstract:Background: Epidermal growth factor receptor (EGFR) activating mutations play crucial roles in the tumorigenesis of human non-small cell lung cancer (NSCLC). The mechanism regarding how EGFR signaling regulates myeloid cell leukemia sequence 1 (Mcl-1) protein stability and ubiquitination remains undefined.Methods: MTS assay was used for natural product library screening. The effect of formononetin on NSCLC cells was determined by MTS assay and soft agar assay. Molecular modeling was performed to analyze the potential different binding modes between formononetin and EGFR WT or mutants. The inhibitory effect of formononetin on EGFR signaling and Mcl-1 expression were examined by immunoblot, in vitro kinase assay, in vitro pulldown and ATP competition assays, co-immunoprecipitation assay, ubiquitination analysis, in vivo xenograft model, and immunohistochemical staining.Findings: Formononetin was identified as an EGFR inhibitor by a 98 commercially available natural product screening. Formononetin suppresses WT and mutant EGFR kinases activity in vitro, ex vivo, and in vivo. Molecular modeling indicates that formononetin docks into the ATP-binding pocket of both WT and mutant EGFR. Formononetin inhibits EGFR-Akt signaling, which in turn activates GSK3β and promotes Mcl-1 phosphorylation in NSCLC cells. Treatment with formononetin enhances the interaction between Mcl-1 and SCFFbw7, which eventually promotes Mcl-1 ubiquitination and degradation. Depletion of either GSK3β or SCFFbw7 compromised formononetin-induced Mcl-1 downregulation. Finally, formononetin inhibits the in vivo tumor growth in a xenograft mouse model.Interpretation: This study highlights the importance of promoting ubiquitination-dependent Mcl-1 turnover might be an alternative strategy to enhance the anti-tumor efficacy of EGFR-TKI.Funding Statement: This work was supported by the National Natural Science Foundation of China (No.81904262, and No.81972837), the Natural Science Foundation of Hunan Province (2018JJ3787, 2018JJ2604, 2019JJ50682).Declaration of Interests: The authors declare that they have no conflict of interest.Ethics Approval Statement: All mice experiments were performed according to strict guidelines established by the Medical Research Animal Ethics Committee, Central South University, China.

Formononetin Restrains Tumorigenesis of Breast Tumor by Restraining STING-NF-κB and Interfering with the Activation of PD-L1

Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation

Formononetin triggers ferroptosis in triple-negative breast cancer cells by regulating the mTORC1/SREBP1/SCD1 pathway

Formononetin Suppresses The Proliferation Of Human Non-Small Cell Lung Cancer Through Induction Of Cell Cycle Arrest And Apoptosis

Formononetin enhances the chemosensitivity of triple negative breast cancer via BTB domain and CNC homolog 1-mediated mitophagy pathways

Suppressive effect of formononetin on platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells.

Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein

Low concentration of formononetin stimulates the proliferation of nasopharyngeal carcinoma cell line CNE2 by upregulating bcl-2 and p-ERK1/2 expression

Formononetin Induces Apoptosis in PC-3 Prostate Cancer Cells Through Enhancing the Bax/Bcl-2 Ratios and Regulating the p38/Akt Pathway

Formononetin induces the mitochondrial apoptosis pathway in prostate cancer cells via downregulation of the IGF-1/IGF-1R signaling pathway

Formononetin Suppresses Hypoxia Inducible Factor-1 Alpha/Inflammatory Cytokines Expression Via Inhibiting Akt Signal Pathway In Multiple Myeloma Cells

STING Agonist Enhances the Efficacy of PD-L1 Monoclonal Antibody in Breast Cancer Immunotherapy by Activating the IFNβ Signaling Pathway

Potential Anticancer Properties and Mechanisms of Action of Formononetin

Low Concentration of Formononetin Promotes Proliferation of Estrogen Receptor-Positive Cells Through an ERα-miR-375-PTEN-ERK1/2-bcl-2 Pathway

In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa

Formononetin Inhibits Tumor Growth by Suppression of EGFR Signaling and Destabilization of Mcl-1 Protein in Non-Small Cell Lung Cancer

Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer

Pterostilbene Simultaneously Induces Apoptosis, Cell Cycle Arrest and Cyto-Protective Autophagy in Breast Cancer Cells.

Long Non-coding RNAs Contribute to the Inhibition of Proliferation and EMT by Pterostilbene in Human Breast Cancer

Inhibition of FGFR Signaling by PD173074 Improves Antitumor Immunity and Impairs Breast Cancer Metastasis

Mechanisms analysis for Formononetin counteracted-Osimertinib resistance in Non-small-cell lung cancer cells: from the insight into the gene transcriptional level